Sales Of Sepsis Diagnostics Is Expected To Reach US$ 1,630 Mn By 2032

From 2022 to 2032, the market for sepsis diagnostics is anticipated to expand at a CAGR of 8%. Rising demand for assays and reagents in various regions is what is driving the market. The industry has a market value of $690 million in 2021, and it is anticipated to increase by 9.4% annually to $755 million in 2022. The market is anticipated to be worth $1,630 million by 2032.

Download FREE Sample Copy of This Report:

Recent product releases have been sparked by the US Food and Drug Administration’s active facilitation of the approval of well-known sepsis diagnostics and treatment alternatives. There is substantial room for expansion for sepsis diagnoses based on microbiology, molecular biology, and immunoassays.

The consistent Sepsis Diagnostics Market report offers sustainable forward-looking growth programs, to ensure business success which is imperative for organizations. With this report, businesses can create a unique space in the global industry and get identified as the most consistent and dedicated growth partner for market research, strategy formulation, and sustainable organizational development. While formulating this report, client business competence is understood adeptly to identify tangible growth opportunities. Moreover, the strategic model around the growth objective is designed by analysts, with detailed route-to-market analysis, competencies to be leveraged and developed, as well as any potential pitfalls.

Key Segments Covered in the Sepsis Diagnostics Industry Report

  • By Product :
    • Blood Culture Media
    • Instruments
    • SAssays & Reagents
  • By Method :
    • Conventional
    • Automated
  • By Pathogen :
    • Gram-Negative Bacterial
    • Gram-Positive Bacterial
    • Fungal
    • Other Pathogens-based
  • By Technology :
    • Microbiology-based
    • Molecular
    • Immunoassays-based
    • Other Technology-based
  • By Region :
    • North America
    • Latin America
    • Europe
    • APEJ
    • Japan
    • Middle East & Africa
Download FREE Sample Copy of This Report:

The global market for sepsis diagnostics is highly fragmented. Leading companies employ a variety of development strategies, such as expanding product portfolios, strategic mergers and acquisitions, expanding manufacturing capabilities, investing in R&D projects, and incorporating technological advances into existing equipment.

Becton Dickinson and Company (BD) announced the BACTECTM Platelet Quality Control Media in 2019, which has been approved by the US Food and Drug Administration for the detection of tainted platelet units in microbiology laboratories, blood banks, and transfusion programmes. The technology, which employs a culture-based technique, enables doctors to identify potentially contaminated platelet donations, thereby lowering the risk of sepsis.

Similarly, Thermo Fisher Scientific released the B.R.A.H.M.S PCT direct point-of-care assay blood test in 2018, allowing for the rapid detection of bacterial infection and sepsis. The test is designed to provide procalcitonin (PCT) measurement in acute care settings to aid in quick management and precise findings for therapeutic solutions. T2 Biosystems Inc. has received clearance for its T2SARS-CoV-2TM Panel, a molecular diagnostic test that identifies the variant of SARS-P1 CoV-2 that was recently validated in the United States. When performed on a fully automated T2Dx® device, this panel has a clinical sensitivity of 95% and a specificity rate of 100%, and it produces results in less than two hours. Because the COVID-19 virus causes sepsis and death, these panels continue to be therapeutically important.

Request Customized Report as Per Your Requirements:

Key Segments Covered in the Sepsis Diagnostics Industry Report

  • Sepsis Diagnostics by Product :
    • Blood Culture Media Sepsis Diagnostics
    • Sepsis Diagnostics Instruments
    • Sepsis Diagnostics Assays & Reagents
  • Sepsis Diagnostics by Method :
    • Conventional Sepsis Diagnostics
    • Automated Sepsis Diagnostics
  • Sepsis Diagnostics by Pathogen :
    • Gram-Negative Bacterial Sepsis Diagnostics
    • Gram-Positive Bacterial Sepsis Diagnostics
    • Fungal Sepsis Diagnostics
    • Other Pathogens-based Sepsis Diagnostics
  • Sepsis Diagnostics by Technology :
    • Microbiology-based Sepsis Diagnostics
    • Molecular Sepsis Diagnostics
    • Immunoassays-based Sepsis Diagnostics
    • Other Technology-based Sepsis Diagnostics
  • Sepsis Diagnostics by Region :
    • North America
    • Latin America
    • Europe
    • APEJ
    • Japan
    • Middle East & Africa

Get Full Access of Complete Report:

Key Obstacles in the Global Sepsis Diagnostics Market
According to the National Institutes of Health, a molecular diagnostic test can cost between USD 300 and USD 3,000, which is significantly more expensive than blood culture tests, which can cost as little as USD 28-35.

Despite the fact that companies are working to develop computer-aided diagnostic instruments for detecting sepsis based on sophisticated technologies such as sepsis molecular diagnostics, public hospitals and scholarly research laboratories cannot afford such systems due to funding constraints. It is also becoming a significant impediment to the growth of the market for sepsis diagnostic equipment.

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583


Leave a Reply

Your email address will not be published. Required fields are marked *